These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11234893)

  • 1. Preclinical evaluation of motexafin lutetium-mediated intraperitoneal photodynamic therapy in a canine model.
    Griffin GM; Zhu T; Solonenko M; Del Piero F; Kapakin A; Busch TM; Yodh A; Polin G; Bauer T; Fraker D; Hahn SM
    Clin Cancer Res; 2001 Feb; 7(2):374-81. PubMed ID: 11234893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy in the canine prostate using motexafin lutetium.
    Hsi RA; Kapatkin A; Strandberg J; Zhu T; Vulcan T; Solonenko M; Rodriguez C; Chang J; Saunders M; Mason N; Hahn S
    Clin Cancer Res; 2001 Mar; 7(3):651-60. PubMed ID: 11297261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photodynamic therapy with motexafin lutetium for rectal cancer: a preclinical model in the dog.
    Ross HM; Smelstoys JA; Davis GJ; Kapatkin AS; Del Piero F; Reineke E; Wang H; Zhu TC; Busch TM; Yodh AG; Hahn SM
    J Surg Res; 2006 Oct; 135(2):323-30. PubMed ID: 16650871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy using Lu-Tex induces apoptosis in vitro, and its effect is potentiated by angiostatin in retinal capillary endothelial cells.
    Renno RZ; Delori FC; Holzer RA; Gragoudas ES; Miller JW
    Invest Ophthalmol Vis Sci; 2000 Nov; 41(12):3963-71. PubMed ID: 11053300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photodynamic therapy with motexafin lutetium (Lu-Tex) reduces experimental graft coronary artery disease.
    Yamaguchi A; Woodburn KW; Hayase M; Hoyt G; Robbins RC
    Transplantation; 2001 Jun; 71(11):1526-32. PubMed ID: 11435960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo photodynamic therapy with the new near-IR absorbing water soluble photosensitizer lutetium texaphyrin and a high intensity pulsed light delivery system.
    Kostenich G; Orenstein A; Roitman L; Malik Z; Ehrenberg B
    J Photochem Photobiol B; 1997 May; 39(1):36-42. PubMed ID: 9210320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of vein graft disease using photodynamic therapy with motexafin lutetium in a rodent isograft model.
    Yamaguchi A; Woodburn KW; Hayase M; Robbins RC
    Circulation; 2000 Nov; 102(19 Suppl 3):III275-80. PubMed ID: 11082401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo reflectance measurement of optical properties, blood oxygenation and motexafin lutetium uptake in canine large bowels, kidneys and prostates.
    Solonenko M; Cheung R; Busch TM; Kachur A; Griffin GM; Vulcan T; Zhu TC; Wang HW; Hahn SM; Yodh AG
    Phys Med Biol; 2002 Mar; 47(6):857-73. PubMed ID: 11936174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer.
    Du KL; Mick R; Busch TM; Zhu TC; Finlay JC; Yu G; Yodh AG; Malkowicz SB; Smith D; Whittington R; Stripp D; Hahn SM
    Lasers Surg Med; 2006 Jun; 38(5):427-34. PubMed ID: 16788929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.
    Verigos K; Stripp DC; Mick R; Zhu TC; Whittington R; Smith D; Dimofte A; Finlay J; Busch TM; Tochner ZA; Malkowicz S; Glatstein E; Hahn SM
    J Environ Pathol Toxicol Oncol; 2006; 25(1-2):373-87. PubMed ID: 16566729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Light dosimetry for intraperitoneal photodynamic therapy in a murine xenograft model of human epithelial ovarian carcinoma.
    Lilge L; Molpus K; Hasan T; Wilson BC
    Photochem Photobiol; 1998 Sep; 68(3):281-8. PubMed ID: 9747583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers.
    Chen Q; Huang Z; Luck D; Beckers J; Brun PH; Wilson BC; Scherz A; Salomon Y; Hetzel FW
    Photochem Photobiol; 2002 Oct; 76(4):438-45. PubMed ID: 12405153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy.
    Sitnik TM; Henderson BW
    Photochem Photobiol; 1998 Apr; 67(4):462-6. PubMed ID: 9559590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipophilic photosensitizer administration via the prostate arteries for photodynamic therapy of the canine prostate.
    Xiao Z; Owen RJ; Liu W; Tulip J; Brown K; Woo T; Moore RB
    Photodiagnosis Photodyn Ther; 2010 Jun; 7(2):106-14. PubMed ID: 20510305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo optical properties of normal canine prostate at 732 nm using motexafin lutetium-mediated photodynamic therapy.
    Zhu TC; Hahn SM; Kapatkin AS; Dimofte A; Rodriguez CE; Vulcan TG; Glatstein E; Hsi RA
    Photochem Photobiol; 2003 Jan; 77(1):81-8. PubMed ID: 12856887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in a rat model.
    Rovers JP; Saarnak AE; Molina A; Schuitmaker JJ; Sterenborg HJ; Terpstra OT
    Br J Cancer; 1999 Oct; 81(4):600-8. PubMed ID: 10574244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal photodynamic therapy in the Fischer 344 rat using 5-aminolevulinic acid and violet laser light: a toxicity study.
    Major AL; Rose GS; Svaasand LO; Lüdicke F; Campana A; van Gemert MJ
    J Photochem Photobiol B; 2002 Mar; 66(2):107-14. PubMed ID: 11897510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer.
    Dimofte A; Zhu TC; Hahn SM; Lustig RA
    Lasers Surg Med; 2002; 31(5):305-12. PubMed ID: 12430147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of recurrence in patients treated with photodynamic therapy for intraperitoneal carcinomatosis and sarcomatosis.
    Wilson JJ; Jones H; Burock M; Smith D; Fraker DL; Metz J; Glatstein E; Hahn SM
    Int J Oncol; 2004 Mar; 24(3):711-7. PubMed ID: 14767557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model.
    Engbrecht BW; Menon C; Kachur AV; Hahn SM; Fraker DL
    Cancer Res; 1999 Sep; 59(17):4334-42. PubMed ID: 10485481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.